To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

Blood pressure is the force of blood pushing against the walls of your arteries as your heart pumps ... consistently fall in the elevated or hypertension stage 1 or 2 categories.

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an outcome. In MR studies, instrumental variables associated with the ...

Hypertension does not directly cause dyspnoea; however it can lead to long-term effects on the heart and arteries ...

"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis" has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...

Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary artery denervation (PADN) as an innovative intervention for ...